CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jul. 02, 2022	Jul. 03, 2021
Cash Flows from Operating Activities:
Net income (loss)	$ 19,877	$ (4,454)
Non-cash items:
Depreciation and amortization	22,447	25,033
Impairment of assets	94	5,144
Share-based compensation expense	5,299	6,828
Amortization of deferred finance costs	797	1,019
Benefit for losses on inventory	(2,075)	(544)
Gain on closing of transaction	0	9,603
Contingent consideration expense	(504)	9,774
Other non-cash operating activities	1,602	4,940
Change in operating assets and liabilities:
Change in accounts receivable	10,358	(5,342)
Change in inventories	15,240	(8,553)
Change in prepaid income taxes	2,118	2,121
Change in other assets and other liabilities	(6,079)	1,256
Change in accounts payable and accrued expenses	(27,181)	(29,299)
Net cash provided by (used in) operating activities	41,993	(1,680)
Cash Flows from Investing Activities:
Capital expenditures	(45,467)	(13,919)
Acquisition	(2,850)	(2,500)
Proceeds from sale of property, plant and equipment	498	568
Other investments	(10,395)	0
Net cash used in investing activities	(58,214)	(15,851)
Cash Flows from Financing Activities:
Repayment of term loan borrowings	(4,375)	(4,375)
Contingent consideration payments	(21,593)	0
Proceeds from employee stock purchase plan	2,459	2,210
Proceeds from exercise of stock options	127	500
Other	(13)	31
Net cash used in financing activities	(23,395)	(1,634)
Effect of exchange rates on cash and cash equivalents	(4,932)	322
Net Change in Cash and Cash Equivalents	(44,548)	(18,843)
Cash and Cash Equivalents at Beginning of Period	259,496	192,305
Cash and Cash Equivalents at End of Period	214,948	173,462
Supplemental Disclosures of Cash Flow Information:
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 38,022	$ 3,203